Skip to main content
. Author manuscript; available in PMC: 2021 Mar 25.
Published in final edited form as: Nat Med. 2020 Apr 27;26(5):712–719. doi: 10.1038/s41591-020-0821-8

Extended Data Fig. 2 |. B7-H3 CAR T cells are highly potent against ATRT cell lines in vitro.

Extended Data Fig. 2 |

a, Cytometric Bead Array of interferon γ release 24 hours after co-culture of B7-H3 CAR T cells or CD19 CAR T cells (control) with ATRT tumor cells (B7-H3 CAR T cells vs. CD19 CAR T cells: BT12 ****p = 5×10−7; BT16 p = 0.086; ATRT-CHB-1 ****p = 5×10−6; VU397 ****p = 5×10−8; CHLA-2 ****p = 9×10−6; CHLA-4 ****p = 5×10−7; CHLA-5 ***p = 9×10−4; ATRT13808 ****p = 7×10−5) (unpaired t-test, two-tailed). b, Killing assay of BT16 ATRT tumor cells when co-cultured with B7-H3 CAR T cells or CD19 CAR T cells (control) at different E:T ratios (B7-H3 CAR T cells vs. CD19 CAR T cells: 1:1 ****p = 5×10−5; 1:4 ***p = 3×10−4; 1:8 ****p = 2×10−6; 1:16: **p = 0.003) (Two-Way Anova). c, Representative images obtained 72 hours after co-culture of BT16 ATRT tumor cells (red) with B7-H3 or CD19 CAR T cells in a 1:4 ratio. d, Killing assay of BT12 ATRT tumor cells when co-cultured with B7-H3 CAR T cells or CD19 CAR T cells (control) at different E:T ratios (B7-H3 CAR T cells vs. CD19 CAR T cells: 5:1 ****p = 3×10−6; 1:1 ****p = 8×10−5; 1:5 ****p = 5×10−6) (Two-Way Anova). All data are means ± s.e.m. (a-d) n = 3 independent samples, experiments have been conducted three times.